Patients, caregivers, and medical professionals can all benefit from having a better understanding of the many types and ...

By 2060, 14 million people will be living with Alzheimer’s, the fifth-leading cause of death in people 65 and older.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

We are at a turning point in the fight against Alzheimer’s disease with the emergence of disease-modifying therapies for ...

There's no single test that can tell when someone has Alzheimer's disease. Identifying the disease in the early stages allows ...

Amyloid-beta and tau proteins have long been associated with Alzheimer's disease. The pathological buildup of these proteins ...

Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Alzheimer's and other dementias take more lives in the United State than breast and prostate cancers combined and the ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...